Amvuttra 25 mg/0.5 mL prefilled syringe Images
Generic Name: vutrisiran
This medication has been identified as Amvuttra 25 mg/0.5 mL prefilled syringe. It is supplied by Alnylam Pharmaceuticals, Inc.
Amvuttra is used in the treatment of Hereditary Amyloidosis; Cardiomyopathy of Transthyretin-Mediated Amyloidosis; Transthyretin-Related Amyloidosis and belongs to the drug class miscellaneous metabolic agents. Amvuttra 25 mg/0.5 mL prefilled syringe is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Amvuttra
- Generic Name
- vutrisiran
- Strength
- 25 mg/0.5 mL prefilled syringe
- Availability
- Prescription only
- Drug Class
- Miscellaneous metabolic agents
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Alnylam Pharmaceuticals, Inc.
- National Drug Code (NDC)
- 71336-1003
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Patisiran
Patisiran (brand name Onpattro) is an injectable treatment for polyneuropathy caused by hereditary ...
Eplontersen
Eplontersen (Wainua) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
More about Amvuttra (vutrisiran)
- Compare alternatives
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.